[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334512-105":59,"doc-detail-334512-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","pan-cancer-characterization-of-cell-free-immune-related-mirna-identified-as-a-robust-biomarker-for-cancer-diagnosis","Pan-cancer characterization of cell-free immune-related miRNA identified as a robust biomarker for cancer diagnosis","","Minimally invasive testing is essential for early cancer detection, impacting patient survival rates significantly. Our study aimed to establish a pioneering cell-free immune-related miRNAs (cf-IRmiRNAs) signature for early cancer detection. We analyzed circulating miRNA profiles from 15,832 participants, including individuals with 13 types of cancer and control, using discovery, validation, test, and external test cohorts. Differentially expressed cf-IRmiRNAs were selected with LASSO and classified using XGBoost.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pan-cancer-characterization-of-cell-free-immune-related-mirna-identified-as-a-robust-biomarker-for-cancer-diagnosis/334512/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pan-cancer-characterization-of-cell-free-immune-related-mirna-identified-as-a-robust-biomarker-for-cancer-diagnosis/334512.png","ImageObject",300,407,{"name":92,"@type":93},"Himbo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the study’s main goal?","Question",{"text":112,"@type":113},"To establish a cf-IRmiRNAs signature for early cancer detection using minimally invasive circulating miRNA profiles.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the data sets organized for model development?",{"text":117,"@type":113},"The 15,832 participants were split into training, validation, and test sets in a 7:2:1 ratio, with an additional external test set of 684 participants.",{"name":119,"@type":110,"acceptedAnswer":120},"Which method selected differential cf-IRmiRNAs and how was the classifier built?",{"text":121,"@type":113},"The study used LASSO to retain 39 cf-IRmiRNAs after identifying 100 differential candidates, then applied five machine learning algorithms with XGBoost for classification.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},334512,1790567673,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":24,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},687197100911,"https://ap-avatar.wpscdn.com/avatar/a000239b6f1da00475?x-image-process=image/resize,m_fixed,w_180,h_180&k=1785132997149421697","Wu et al. Molecular Cancer (2024) 23:31 Molecular Cancer  \n[https://doi.org/10.1186/s12943-023-01915-7](https://doi.org/10.1186/s12943-023-01915-7)  \nCORRESPONDENCE Open Access  \nPan-cancer characterization of cell-free   immune-related miRNA identified as a robust biomarker for cancer diagnosis  \nPeng Wu 1†, Chaoqi Zhang 1†, Xiaoya Tang 1†, Dongyu Li 1,2, Guochao Zhang 1, Xiaohui Zi 1, Jingjing Liu 1, Enzhi Yin 1, Jiapeng Zhao2, Pan Wang 1, Le Wang3, Ruirui Li4, Yue Wu5, Nan Sun 1* and Jie He 1*  \nAbstract  \nMinimally invasive testing is essential for early cancer detection, impacting patient survival rates significantly. Our study aimed to establish a pioneering cell-free immune-related miRNAs (cf-IRmiRNAs) signature for early cancer detection. We analyzed circulating miRNA profiles from 15,832 participants, including individuals with 13 types of cancer and control. The data was randomly divided into training, validation, and test sets (7:2:1), with an additional external test set of 684 participants. In the discovery phase, we identified 100 differential ly expressed cf-IRmiRNAs between the malignant and non-malignant, retaining 39 using the least absolute shrinkage and selection operator (LASSO) method. Five machine learning algorithms were adopted to construct cf-IRmiRNAs signature, and the diagnostic classifies based on XGBoost algorithm showed the excellent performance for cancer detection in the validation set (AUC: 0. 984, CI: 0.980–0. 989), determined through 5-fold cross-validation and grid search. Further evaluation in the test and external test sets confirmed the reliability and efficacy of the classifier (AUC: 0.980 to 1. 000) . The classifier successfully detected early-stage cancers, particularly lung, prostate, and gastric cancers. It also distinguished between benign and malignant tumors. This study represents the largest and most comprehensive pan-cancer analysis on cf-IRmiRNAs, offering a promising non-invasive diagnostic biomarker for early cancer detection and potential impact on clinical practice.  \nKeywords Cell-free immune-related miRNAs, Pan-cancer analysis, Machine learning algorithms, Early detection of cancers  \n†Peng Wu, Chaoqi Zhang and Xiaoya Tang contributed equally to this work.  \n*Correspondence: Nan Sun [sunnan@cicams.ac.cn](sunnan@cicams.ac.cn)[ ](sunnan@cicams.ac.cn)Jie He [prof.jiehe@gmail.com](prof.jiehe@gmail.com)  \n1Department of Thoracic Surgery, National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China  \n24+4 Medical Doctor Program, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China  \n3Department of Otolaryngology-Head and Neck Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China 4Department of Pathology, National Clinical Research Center for Cancer/ Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China 5Department of Clinical Laboratory, National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use,","cbCaieFDvo7UOR7I","https://ap.wps.com/l/cbCaieFDvo7UOR7I","pdf",4839120,"English","# Abstract\n## Study design and cohorts\n## Feature discovery and signature building\n## Machine-learning classification and evaluation\n## Performance in early-stage and distinguishing groups","[{\"question\":\"What is the study’s main goal?\",\"answer\":\"To establish a cf-IRmiRNAs signature for early cancer detection using minimally invasive circulating miRNA profiles.\"},{\"question\":\"How were the data sets organized for model development?\",\"answer\":\"The 15,832 participants were split into training, validation, and test sets in a 7:2:1 ratio, with an additional external test set of 684 participants.\"},{\"question\":\"Which method selected differential cf-IRmiRNAs and how was the classifier built?\",\"answer\":\"The study used LASSO to retain 39 cf-IRmiRNAs after identifying 100 differential candidates, then applied five machine learning algorithms with XGBoost for classification.\"}]","Pan-cancer characterization of cell-free immune-related miRNA identified as a robust biomarker for cancer diagnosis | PDF",1790006989,13]